New combo targets Hard-to-Treat stomach tumors

NCT ID NCT05245968

Ongoing Disease control Sponsor: Taiho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see if the combination can slow tumor growth. About 78 participants will be enrolled across different treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pimitespib (TAS-116) and imatinib
What this could lead to: If successful, this combination could offer a new treatment option for people with GIST whose cancer has stopped responding to imatinib alone.
What could go wrong: This is an early Phase 1 trial with a small number of participants, so it is not yet clear if the combination is safe or effective. Side effects from the drugs may also limit their use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS

Contacts and locations

Locations

Alfred Health

Melbourne, Australia
Beijing Cancer Hospital

Beijing, China
Flinders Medical Center

Adelaide, Australia
Fudan University, Shanghai Cancer Center

Shanghai, China
Hokkaido University Hospital

Hokkaido, Japan
Kaohsiung Medical University Hospital

Kaohsiung City, Taiwan
Kumamoto University Hospital

Kumamoto, Japan
Linkou Chang Gung Memorial Hospital

Linkou District, Taiwan
National Cancer Center Hospital

Tokyo, Japan
National Cancer Center Hospital East

Chiba, Japan
National University Cancer Institute

Singapore, Singapore
Osaka University Hospital

Osaka, Japan
Taipei Veterans General Hospital

Taipei, Taiwan
The Cancer Institute Hospital of JFCR

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.